Roche Holding AG

08/24/2022 | Press release | Distributed by Public on 08/23/2022 23:11

Roche's VENTANA PD-L1 (SP263) test gains CE label expansion as a companion diagnostic to identify non-small cell lung cancer patients eligible for Tecentriq

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.